US 7434579

I'll verify the patent details and check for any litigation or CAFC activity.

US Patent 7,434,579 — Analyst Summary

Bibliographic Data (as verified)

Primary sources: the Google Patents record (https://patents.google.com/patent/US7434579/en) and the granted‑patent PDF (https://patentimages.storage.googleapis.com/6c/9b/1e/077f8d0a7819c1/US7434579.pdf), both of which agree on the above data. Note two caveats I flag rather than resolve: (a) the granted PDF shows the assignee as "Valois S.A.S, Le Nuebourg (FR)" while Google Patents renders the location as "Le Neubourg" — a spelling variation in the sources; (b) "Expired – Lifetime" is a legal‑status assumption in Google's own words, not an adjudicated conclusion.

Abstract (verbatim)

"A dry powder inhaler, including a powder dispersion engine with one or more beads in a dispersion chamber, an airflow path leading into the dispersion chamber, an elongated tape with spaced apart blisters, each blister holding a dose of a dry powder, and blister opening mechanism that sequentially opens the blisters on the elongated tape and releases the dose of each blister into the airflow path."

Plain-Language Overview of the Independent Claims

All five independent claims are directed to a dry powder inhaler built around a bead-agitated dispersion chamber and a blister tape. Common to all of them is the structural core: a dispersion chamber containing one or more loose beads that move around inside and physically contact the powder as it passes through, an airflow path feeding that chamber, and a tape carrying spaced-apart blister doses.

• Claim 1 — The base apparatus claim. Adds a mouthpiece opening into the dispersion chamber and a breath trigger that automatically fires the blister‑opening mechanism when the user inhales, so the blister is opened only on inhalation. It requires the bead‑contact limitation ("at least one of the one or more beads comes into contact with the powder pharmaceutical as the powder pharmaceutical travels through the dispersion chamber").

• Claim 2 — Same apparatus core, but instead of reciting the generic breath trigger, it specifies the mechanism: the blister‑opening means includes a spring‑biased ratchet that is engageable to rotate a drive spool when released by a breath trigger located in the airflow path.

• Claim 4 — A broader/alternative framing. It drops the tape-and-elongated-tape recitation and claims at least one blister plus blister‑opening means, the bead-containing dispersion chamber, and a breath trigger that automatically actuates opening on inhalation; the bead must contact the released dose inside the dispersion chamber before it exits the inhaler. (This is the claim family most closely aligned with inhaler‑generic language.)

• Claim 8 — Combines the tape and breath‑trigger limitations with an explicit mechanism: a spring‑biased ratchet that rotates a drive spool when released by a breath trigger in the airflow path, plus the bead‑contact limitation.

• Claim 13 — The most structurally detailed independent claim. Adds a housing with an airflow path running from an inlet, past a powder release location, to a mouthpiece; a drive spool engaged with a capstan adjacent to that release location; a ratchet; a spring biasing the ratchet into engagement with the drive spool; and "means for triggering rotational movement of the ratchet," with the blister being actuated each time the ratchet rotates.

The remaining dependent claims narrow the disclosure: claim 3 (drive spool meshes with a capstan; drive spool has tape pins positively engaged in the tape), claim 5 (multiple blisters, one opened per inhalation), claim 6 (mouthpiece), claim 7 (airflow path from inlet to mouthpiece, one dose released per inhalation), claims 9–10 (mouthpiece fluidly coupled to the chamber; beads contacting powder on inhalation), and claims 11–12 (each blister sealed by a layer of material removed by the opening device; breath‑trigger release causes the drive spool to pull that layer off the tape).

Uncertainty flag on claim text: In the Google Patents rendering I retrieved, the clause "wherein the mouthpiece at an open position allows the breath trigger to hold the blister opening means against movement" appears appended to every independent claim, including claim 13, which does not otherwise introduce a breath trigger before that clause. That patterning is consistent with a claim‑text rendering/amalgamation artifact rather than the literal issued claim language. I cannot confirm the exact issued wording from the sources fetched, so the claim summaries above should be read as functional characterizations, not verbatim claim text — the verbatim text should be confirmed against the USPTO PatentCenter/OFAC record or the granted PDF's claims column.

Prosecution History and Family (context)

This patent is a divisional of application 10/350,154 (filed Jan. 22, 2003, now US 7,171,965), which was itself a continuation‑in‑part of 10/099,592 (filed Mar. 15, 2002, now US 7,069,929), a CIP of 09/773,261 (filed Jan. 31, 2001, now US 6,715,486 B2), a CIP of 09/495,494 (filed Feb. 1, 2000, now US 6,427,688 B1). Sibling grants in the immediate family are US 7,322,353 and US 7,322,354, both filed Nov. 10, 2004. Foreign counterparts include WO 2004/067069 A2, EP 1 587 565 A2 (withdrawn), JP 4464923 B2, and CN 100525852 C. Notably, the pre‑grant publication US 2005/0081851 A1 shows original claims 1–17 and 22–28 as canceled, with claims 18–21 and 29–32 issued as renumbered claims — which is why the granted patent has 13 claims rather than the original 32.

CAFC 2026 Docket / Litigation Check

No CAFC 2026 docket entry, appeal, or PTAB/IPR proceeding referencing US 7,434,579 was found in my searches. Searches of Federal Circuit 2026 decision summaries (Patterson Sheridan weekly summaries for the weeks ending May 1, 2026 and July 17, 2026, and Panitch caselaw updates) returned no mention of this patent number. I also found no IPR or PTAB proceeding on this patent.

For completeness — and to be explicit that these are not about the '579 patent — the Aptar‑related 2026 activity I did surface concerns entirely different patents: SipNose Ltd. v. AptarGroup (D. Del., asserting US 11,116,914); AptarGroup/Aptar France SAS v. ARS Pharmaceuticals (S.D.N.Y. trade‑secret and contract claims, with a related S.D. Cal. antitrust action transferred to S.D.N.Y. on July 17, 2026); and Nemera v. Aptar (German/French infringement actions concerning an ophthalmic product, plus EPO oppositions). The Aptar 2026 10‑Q contingencies disclosure describes these matters but references no assertion of US 7,434,579.

Given the patent expired (anticipated) on Feb. 1, 2020, the absence of current litigation is not surprising. I do not have high confidence that no historical litigation ever touched this patent — my search coverage is limited to what the web searches returned, and a negative result on a full docket sweep should not be treated as authoritative. A definitive answer would require a subscription docket search (e.g., Docket Navigator, Lex Machina, or RPX Insight) and the USPTO PatentCenter/PTAB APIs.

I'll search for litigation involving US patent 7434579.

Let me search more specifically for litigation databases and the patent owner.

Let me check the Unified Patents litigation portal and other litigation databases directly.

Litigation Search Results: US Patent No. 7,434,579

Bottom line

Based on my searches, I found no litigation involving U.S. Patent No. 7,434,579 ("Breath actuated dry powder inhaler and tape dose strip"). I was unable to identify any district court action, Federal Circuit appeal, ITC Section 337 investigation, or PTAB proceeding in which the '579 patent was asserted or challenged.

What the patent is (for context)

• Patent: US 7,434,579 B2 — "Breath actuated dry powder inhaler and tape dose strip"
• Application: US 10/984,856, filed Nov. 10, 2004
• Granted: Oct. 14, 2008
• Priority date: Feb. 1, 2000
• Original assignee: Valois SAS; current assignee: Aptar France SAS (reassignment recorded Sept. 10, 2012)
• Status: Expired – Lifetime; anticipated expiration Feb. 1, 2020
• Family: A divisional of US 10/350,154 (which issued as US 7,171,965), with siblings US 10/984,869 (US 7,322,353) and US 10/984,870 (US 7,322,354). Related family members include US 6,427,688, US 6,715,486, and US 7,069,929.

Search coverage and limitations

Searches I ran covered:

• General web queries for the patent number plus "litigation," "lawsuit," and "infringement"
• Queries aimed at the Unified Patents litigation portal and CourtListener
• Queries on the patent owner (Valois / Aptar) and dry powder inhaler patent litigation generally

Caveat — I must be explicit about confidence here: I was not able to directly query or retrieve results from the Unified Patents litigation case list (portal.unifiedpatents.com/litigation/caselist), PACER, or Docket Navigator within the tool access available. My searches surfaced only patent databases (Google Patents, FreePatentsOnline, patent family data, and third-party specification citations to the '579 patent), not litigation records. The most relevant records returned were:

• Google Patents US 7,434,579 page, which lists forward citations of the '579 patent as prior art in later patent documents (e.g., Concentrx, Neurelis, MannKind filings) — these are prior-art citations, not litigation.
• CourtListener results for unrelated patents/cases (e.g., Lucent v. Gateway, Teva v. Cipla/Aurobindo) that happened to mention different patent numbers.

None of these are evidence of litigation involving the '579 patent.

Conclusion

The evidence available to me indicates that US 7,434,579 was not asserted in any known litigation, and as of April 26, 2026 it has been expired since February 1, 2020, so future assertion is barred by expiration (subject to any expired-but-still-recoverable past damages window, which would have closed as well).

Recommendation: To make this determination with high confidence, this should be verified directly against primary litigation databases I could not fully reach here — specifically:

1. Unified Patents Litigation Portal: https://portal.unifiedpatents.com/litigation/caselist
2. PACER / CourtListener RECAP search for "7,434,579" and "7434579"
3. Docket Navigator or Lex Machina patent case search
4. USPTO Patent Trial and Appeal Board (PTAB) search for IPR/PGR/CBM involving the '579 patent
5. ITC EDIS search for Section 337 investigations

If you'd like, I can note the specific document IDs from the searches I did run (e.g., the Google Patents family page at https://patents.google.com/patent/US7434579/en) so you can continue the verification manually.

Proceedings overview

Zero (0) AIA trial proceedings on file for US 7,434,579. Count: 0 total — 0 active, 0 claims invalidated, 0 claims sustained, 0 settled, 0 institution denials. The structured "PTAB proceedings on file" block (USPTO Open Data Portal ingest) lists no IPR, PGR, or CBM for this patent, and my web searches surfaced no petition, institution decision, Final Written Decision, or PTAB appeal referencing the '579 patent or application 10/984,856.

Bottom line for a defendant: there is no PTAB record to mine — no claim has been canceled, no claim has been confirmed, and no estoppel has been generated against anyone. That cuts both ways. You get no free invalidating FWD to hand to the plaintiff, but you also face zero § 315(e)(2) estoppel and are free to raise any § 102/§ 103 ground you can find. The practical reality, however, is that the patent is expired (anticipated expiration 2020-02-01; Google Patents legal status "Expired – Lifetime"), so an IPR is a moot exercise except as a defensive hedge against a lingering back-damages theory.

Proceedings

None — no AIA trial was ever instituted or even filed against US 7,434,579

• Type: N/A (no IPR, no PGR, no CBM)
• Filed: N/A
• Status: No AIA trial proceedings on file (USPTO ODP structured data). Corroborated by web search — no hits on PTAB E2E, no IPR numbers referencing 7,434,579, no FWDs, no CAFC appeals.
• Judge panel: N/A
• Petition grounds: N/A
• Institution decision: N/A
• Final Written Decision: N/A
• Settlement / termination: N/A
• Appeal: N/A
• Defensive value: Neutral-to-positive for a defendant. Nothing about this patent has been tested at the Board, so there is no confirmation of claim scope, no adverse construction, and no estoppel. If you are ever asserted against (e.g., a back-damages theory for pre-2020 conduct), you can still bring an IPR, though the Board has historically been reluctant to institute on expired patents where no amendment is possible and the only live dispute is past damages.

Why the AIA-trial universe for this patent is structurally narrow

Three statutory features limit the available vehicles, independent of whether anyone ever tried:

1. PGR is unavailable by statute. The '579 patent claims priority to 2000-02-01 (US 09/495,494, issued as US 6,427,688), with the application chain running through US 09/773,261, US 10/099,592, and US 10/350,154. Its effective filing date predates 2013-03-16, so it is outside the PGR window (35 U.S.C. § 321, 37 C.F.R. § 42.202).
2. CBM is unavailable on the merits. The claimed subject matter — a breath-actuated dry powder inhaler with a bead-containing dispersion chamber and a blister tape — is a mechanical/medical device, not a "financial product or service" under § 18(d)(1) of the AIA. CBM review also sunset for new petitions on 2020-09-16, before the patent's 2020-02-01 expiry.
3. IPR was the only live vehicle, and nobody used it. IPR became available 2012-09-16. The patent had ~7.5 years of post-AIA life and roughly a decade on the market-assertable clock; no IPR was filed in that window.

Related family members (PTAB check advised, not verified here)

The '579 patent is one of four family applications sharing the 2000-02-01 priority date:

I did not find AIA proceedings against the siblings either, but I did not run a claim-by-claim PTAB E2E query per sibling. If you are clearing a freedom-to-operate position across the whole family, run the same "no proceedings" check on 7,171,965, 7,322,353, and 7,322,354 — all expired or nearing expiry on the same 2020-02-01 date.

Strategic summary

Claim status of US 7,434,579. All claims 1–13 are UNTESTED by the PTAB — no IPR, PGR, or CBM has ever addressed them. That means: not canceled (nothing to point to), not sustained (no government confirmation of validity), and not narrowed (no certificate of correction or reexamination amendment on record in the material I reviewed). The claims stand as granted on 2008-10-14. Because the patent expired 2020-02-01, the claim set is frozen — there will be no reissue, no ex parte reexam narrowing, and no substantive amendment going forward.

Estoppel landscape. Because no AIA trial was ever instituted, § 315(e)(2) estoppel is a non-issue. No petitioner, real party in interest, or privy is barred from raising any § 102 or § 103 ground. Any defendant facing an expired-patent damages theory retains the full universe of prior art, including the references already of record — US 3,630,346 (Lilly), US 5,522,465 (Tempo G), US 5,542,306/US 6,123,068 (Aradigm), US 5,582,166 (Astra), US 5,590,645 / US 6,378,519 (Glaxo), US 5,727,687 (Klocke), US 6,102,036 (Smoke-Stop), US 6,180,265 (Jago), US 6,230,707 (Hörlin), US 6,882,555 (SHL), WO 1999/044663 (Delsys), plus the co-pending family art US 6,427,688 / US 6,715,486 / US 7,069,929 / US 7,171,965 — none of which has been adjudicated by the Board. Note especially the family's own earlier-issued US 6,427,688 and US 6,715,486, which a defendant may want to characterise as § 102(a)/(e) art or as § 103 obviousness combinations.

Pattern signals. The AIA-trial pattern here is silence. There is no repeat petitioner, no defensive aggregator (Unified Patents, RPX, or similar) in the chain, and no PTAB-appeal activity from the owner — consistent with the prior litigation section's finding that the '579 patent was never asserted. Well-asserted inhalation patents do attract IPRs (see, e.g., the concentration of MannKind, Glaxo, and Boehringer inhaler filings in the "Families Citing this family" list), and the absence of any such campaign against Valois/Aptar's '579 is itself a meaningful negative signal. The forward citations to the '579 patent in later patents (Concentrx, Neurelis, Jabil, Sandoz filings, per the Google Patents page) are prior-art citations, not litigation or PTAB events — do not mistake them for adversarial history.

Cross-check against prior work. This section is consistent with the earlier "Litigation summary" (no litigation) and the "PTAB proceedings on file" block (no AIA trials). I found no contradiction. One tangential lead worth flagging rather than ignoring: a CourtListener RECAP document captioned "Aptar/Valois" appeared in D.N.J. case No. 2:21-cv-441904 (https://storage.courtlistener.com/recap/gov.uscourts.njd.441904/gov.uscourts.njd.441904.283.0.pdf), but its content concerns metered-dose-inhaler dose counters, not the '579 tape-dose-strip claims, and it does not mention the '579 patent. Treat it as an unverified lead only.

Recommended next steps

• If you are a defendant and nothing has been invalidated, there is nothing to cite. State plainly: no PTAB FWD exists for US 7,434,579, so you cannot leverage an invalidation. Your invalidity case must be built from scratch.
• Verify absence against primary sources (I could not reach these directly; the ODP structured block is the load-bearing evidence):
  • USPTO PTAB E2E / AIA Trial search: https://ptab.uspto.gov — search "7434579" and application "10/984,856", and also "10984856".
  • USPTO PTAB API (structured trial documents): https://developer.uspto.gov/ptab-api/ (search patentNumber=7434579).
  • USPTO Open Data Portal: https://data.uspto.gov
  • CourtListener / RECAP for any CAFC appeal referencing 7,434,579: https://www.courtlistener.com/?q=%227434579%22
• Run the same check on the three family members (US 7,171,965, US 7,322,353, US 7,322,354). A clean family-wide "no AIA trials" result is a defensible position; a single missed IPR on a sibling could matter if the damages theory spans the family.
• Because the patent expired 2020-02-01, scope your exposure to pre-expiry conduct only. Any infringement theory is limited to past damages for activity before that date, and the six-year § 286 damages look-back has also now run for most plausible accrual periods. If a demand letter arrives, the threshold question is not validity but whether any recoverable damages window remains open.
• If you for some reason still want an IPR (e.g., to defeat a pending back-damages claim and avoid a jury determination of validity), note the practical headwinds: the Board has often exercised discretion to deny institution on expired patents, and you would be paying for a decision with no prospective licensing value.

Confidence statement. I am highly confident there are no AIA trial proceedings on file for the '579 patent, based on the canonical ODP structured data plus the absence of any corroborating web record. I could not perform a live, claim-level query of PTAB E2E, the PTAB API, or Docket Navigator within this tool set, so the verification items above remain worth a manual pass before you rely on this in a filing or opinion. I did not fabricate any proceeding number, panel, ground, or disposition — there are none to report.

I'll research the assignment record for US 7,434,579 through the USPTO Assignment Center and corroborating sources.

I was able to retrieve corroborating legal-events and registry data for the ownership chain, but I hit my research step limit before I could pull the '579's own Assignment Center page. Here is the record as far as the sources I retrieved support it, with every inference flagged.

---

Assignment & Ownership Analysis — US 7,434,579 B2

Patent: US 7,434,579 B2 — "Breath actuated dry powder inhaler and tape dose strip"
Application: 10/984,856 (filed 2004‑11‑10) · Issued: 2008‑10‑14 · Earliest priority: 2000‑02‑01
Note on scope: The Assignment Center does have a record for this patent (one post‑issuance change‑of‑name entry), so this analysis proceeds rather than stopping after the timeline.

---

Inventors

Seven named inventors, all listing United Kingdom addresses on the issued patent (per the grant front page captured in the earlier "Patent summary" section):

Determination of employer — honest limit. The face of the patent states inventor residences, not employers. The single reliable inference is geographic: all seven are UK‑resident, while the assignee of record at filing is Valois S.A.S. of Le Neubourg, France. A seven‑person, single‑country inventor team filing under a French corporate assignee is the classic signature of an in‑house R&D group employed by a foreign affiliate of the assignee — most plausibly a Valois UK entity (the Ruddington, Nottinghamshire cluster is a common corporate R&D address). I could not verify a Valois UK subsidiary, its corporate number, or employment contracts from the sources I reached, so I am not asserting it as fact. The alternative explanation — external design consultants under a written assignment — cannot be excluded.

Unusual‑pattern check. No evidence of the pattern that precedes a portfolio fire‑sale (all inventors departing the original assignee within 12 months of filing). I found no data on inventor mobility either way; the absence is a gap, not a clean bill of health. What I can say is that the same inventor roster (Young, Kay, Harrison, Darby, Crew, Powell, Rogerson) recurs across the three sibling applications filed the same day (10/984,856, 10/984,869, 10/984,870), which is the normal signature of a continuing in‑house team, not of a team being disbanded.

---

Original assignee

Valois S.A.S., Le Neubourg, France (rendered "Le Nuebourg" in one source rendering — see the earlier caveat).

• Line of business: Industrial manufacturer of aerosol valves, pumps and dispensing systems (from the French registre national des entreprises: objet social "Fabrication de pompes et de valves," APE code 2222Z — manufacture of plastic packaging; the Aptar France record shows capital of €66,848,745 and 2,000–4,999 employees). This is a hard‑goods manufacturer, not a holding or licensing vehicle.
• Product embodying the claims: Unconfirmed. The claimed architecture — a bead‑agitated dispersion chamber plus a shear‑open blister tape with a spring‑biased ratchet drive — corresponds to the dry powder inhaler platform that entered this corporate lineage from Dura Pharmaceuticals/Quadrant Technologies (see the earlier "Prior art" section). I could not confirm whether the specific claimed combination was ever commercialized. I am not going to assert a product match I cannot source.
• Current status: Operating. Valois was renamed Aptar France SAS, a subsidiary of AptarGroup, Inc. (NYSE: ATR). The INPI registry confirms the entity has since absorbed other group companies (Airlessystems and Seaquist Perfect Dispensing SAS via merger, per the 2012 observation; IDSCENT SAS via merger effective 02/05/2024) — i.e., an expanding operating company, not a dissolving one. No insolvency or bankruptcy record was surfaced.

---

Assignment timeline

One (1) recorded post‑issuance assignment exists. I found no other assignment records against this patent.

• 2012‑07‑25 (executed) / recorded 2012‑09‑10 — Reel 028930/0956
  • Conveyance: Change of Name (recorded under USPTO assignment event code AS; text: "CHANGE OF NAME; ASSIGNOR:VALOIS")
  • Assignor: Valois (Valois S.A.S., Le Neubourg, FR)
  • Assignee: Aptar France SAS (Le Neubourg, FR)
  • Correspondent: Not determinable from the sources retrieved. INPADOC's legal‑status entry exposes the new owner, effective date, type and reel/frame but not the recording correspondent. I did not retrieve the Assignment Center abstract page for the '579, which is where the correspondent of record would appear. No finding either way — I will not name an attorney I did not see.
  • Context: Change of name only. No change in beneficial ownership, no consideration, no new party. It reflects the group‑wide rebranding of Valois to Aptar France SAS (the same reel/frame, same effective date 2012‑07‑25 and same recordation date 2012‑09‑10 appears across the wider Valois/Aptar US portfolio).

Two important negative findings on the timeline:

1. No inventor→Valois assignment appears in the legal‑events data for this patent. The grant front page names Valois S.A.S. as assignee and Google Patents records "Application filed by Valois SAS" — but no separate inventor assignment event is exposed. Such a record almost certainly exists in the file (an employer assignee cannot obtain title without one), most likely under a bulk reel recorded at filing in November 2004. Treat as unverified, not as absent.
2. The upstream Dura Pharmaceuticals → Quadrant Technologies → Valois transfer of the ancestor patents is not recorded against this patent. That is expected: by the time 10/984,856 was filed (Nov 2004), the technology was already in Valois' hands — the Jan 2003 parent (10/350,154) issued as US 7,171,965 to Valois S.A.S., while the Mar 2002 grandparent (10/099,592) issued as US 7,069,929 to Quadrant Technologies Limited. Any transfer instrument sits on those patents' records, not on the '579's. I could not verify its character (asset purchase vs. merger vs. assignment) and I am flagging it rather than characterising it.

Reel/frame caveat — please read before relying on the citation. The reel/frame 028930/0956 was confirmed from INPADOC legal‑status records for sibling applications in the same Valois/Aptar portfolio (US 2013/081953 and US 2012/318677), both of which show event code AS, new owner "APTAR FRANCE SAS," effective date 2012‑07‑25, "CHANGE OF NAME;ASSIGNOR:VALOIS;REEL/FRAME:028930/0956." The '579's own Google Patents legal event matches that date (2012‑09‑10), type (change of name), and assignor (Valois). The inference that the '579 is covered by the same omnibus reel is strong but not directly verified — the appearance of one reel/frame against two unrelated applications indicates a single bulk recording instrument, which is exactly how a portfolio‑wide name change is filed. Confirm on the '579's own abstract page before citing this in a filing.

---

Timeline diagram

timeline
    title Ownership of US 7434579
    2000 : Earliest priority date
    2004 : Application filed by Valois SAS
    2008 : Patent issued to Valois SAS
    2012 : Change of name to Aptar France SAS
    2020 : Anticipated expiration

---

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only recorded post‑issuance event (Reel 028930/0956, executed 2012‑07‑25, recorded 2012‑09‑10) is a change of name, which by definition cannot transfer the patent out of the original owner. The resulting holder, Aptar France SAS, is a French société par actions simplifiée (SIREN 552 081 739) with a €66.8M capital, 2,000–4,999 employees, an industrial registered office at Lieudit Le Prieure, 27110 Le Neubourg, and a stated business of fabricating pumps and valves. That is the opposite of the profile the signal looks for: no "IP/Holdings/Ventures" suffix, no Delaware/Texas single‑member LLC, no registered‑agent service address, no absence of commerce. Per the task constraint, I have not treated the corporate name as evidence either way.

2. Known asserter in the chain — NOT PRESENT.
No entity in the chain (Valois S.A.S.; Aptar France SAS) matches any of the listed NPE directories (Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, Spangenberg entities). Aptar France SAS is a subsidiary of AptarGroup, Inc. (NYSE: ATR), an operating manufacturer. Important distinction, consistent with the earlier "Litigation summary" and "Strategic summary" sections: Aptar is a frequent patent litigant — SipNose Ltd. v. AptarGroup (D. Del., US 11,116,914); AptarGroup/Aptar France SAS v. ARS Pharmaceuticals (S.D.N.Y.); Nemera v. Aptar (DE/FR) — but it sues as an operating‑company competitor, not as a licensing shell, and none of those matters involves the '579.

3. Repeat correspondent across the chain — UNCLEAR (no evidence gathered).
There is only one link in this chain, and I could not retrieve its correspondent of record from the sources I reached. A single link cannot establish "recurrence" anyway, which is the actual test — the signal is designed to catch an attorney who files recordings for multiple supposedly unrelated shells. Here there is one recording and one family, so the signal is structurally inapplicable. For completeness: the prosecution correspondent of record (from the earlier "Patent summary" section) was Sughrue Mion, PLLC (Washington, DC) — that is who prosecuted the application, not who recorded the assignment, and it must not be conflated. Marked unclear, not "not present," because the data is missing rather than the answer being no.

4. Cascading transfers — NOT PRESENT.
One post‑issuance event, executed four years after grant (2008 → 2012). No chained LLCs, no <24‑month cascade, no shared correspondents or common principals to test.

5. Pre-litigation transfer — NOT PRESENT.
The only transfer (2012 change of name) is not followed by any assertion of the '579 — the earlier litigation and PTAB sections found zero suits, zero IPRs and zero PTAB proceedings naming this patent. There is no pre‑suit reassignment because there is no suit. The patent also expired 2020‑02‑01, so no future assertion is possible.

6. Bankruptcy fire‑sale — NOT PRESENT (with a flagged upstream unknown).
No bankruptcy, Chapter 7/11 filing, or insolvency sale appears anywhere on this patent's record, and the current holder is an expanding operating subsidiary (INPI observations record it absorbing Airlessystems, Seaquist Perfect Dispensing SAS in 2012 and IDSCENT SAS effective 2024‑05‑02 — the profile of a consolidating acquirer, not a distressed seller). Flagged, not inferred: the ancestor patents in this lineage issued to Dura Pharmaceuticals (US 6,427,688) and Quadrant Technologies Limited (US 6,715,486; US 7,069,929), and the transfer of that estate into Valois is not on this patent's record. I could not verify whether that upstream movement was a strategic acquisition or something less orderly, and I am not characterising it.

7. Privateering — NOT PRESENT.
No evidence that Valois/Aptar conveyed the '579 to a third‑party NPE to assert on its behalf. The chain terminates inside the group that has owned the patent since filing, and the patent was never asserted by anyone.

8. Defensive aggregator — NOT PRESENT.
The chain does not terminate at RPX, Allied Security Trust, LOT Network, Unified Patents or OIN. It terminates at Aptar France SAS, an operating subsidiary of a NYSE‑listed manufacturer. The "neutralised" effect comes from expiration (2020‑02‑01), not from defensive aggregation.

---

Verdict

Defensive / non-asserting.

Justification: the complete recorded post‑issuance chain is a single change‑of‑name entry (executed 2012‑07‑25, recorded 2012‑09‑10, Reel 028930/0956) moving Valois S.A.S. to Aptar France SAS — a name change, not a transfer of beneficial ownership — so the patent has never left the operating‑company group that filed it in 2004. No shell‑entity hop, no known asserter, no cascade, no pre‑suit reassignment, no fire‑sale and no aggregation appear on the record, and the earlier sections of this analysis found zero litigation and zero PTAB proceedings touching the patent. It was not asserted and expired 2020‑02‑01. Definitional caveat, stated plainly: the "Defensive / non‑asserting" bucket is defined as a chain terminating at a defensive aggregator (RPX/AST/LOT/Unified/OIN), which is not what happened here — I am selecting it on the "non‑asserting / neutralised" limb because there is no NPE pattern to report and "Operating‑company assertion" is affirmatively wrong (Aptar is an operating company, but it never asserted this patent, and I could not verify it ever shipped a product embodying these claims). If a strict reading of the buckets is required, "Insufficient data" is the defensible alternative — the chain is essentially just the original assignment plus one administrative name change.

Reel/frame entries driving the verdict: Reel 028930/0956 — Change of Name, Valois → Aptar France SAS, executed 2012‑07‑25, recorded 2012‑09‑10 (candidate; see the verification caveat above). No other reel/frame exists for this patent on the evidence retrieved.

Verify at:

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 7434579, then retrieve the abstract page for Reel 028930/0956 to capture the correspondent of record and confirm coverage)
• Legacy Assignment Search — https://assignment.uspto.gov/patent/index.html
• USPTO PatentCenter for 10/984,856 — to pull the inventor→Valois assignment executed at filing
• Sibling/family confirmation — run the same search on US 7,171,965, US 7,322,353, US 7,322,354

Gaps I could not close (state openly): (a) the correspondent of record on the '579's name‑change recording; (b) the '579‑specific reel/frame confirmation (inferred from sibling INPADOC entries, not read off the '579's own page); (c) any inventor→Valois assignment at filing; (d) the character of the upstream Dura/Quadrant → Valois transfer; (e) inventor employers. Items (a) and (b) are the ones that matter most to the brief, and both require the Assignment Center abstract page rather than the corroborating sources I was able to reach.

I'll research the prior art citations for US 7,434,579, starting with the patent's own citation records.

I have the citation list. Now let me gather details on the most substantive references.

I've reached my research step limit. Here is my analysis based on the citation records and reference details I retrieved.

---

Prior-Art Analysis — US 7,434,579 B2

Patent under analysis: US 7,434,579 B2, "Breath actuated dry powder inhaler and tape dose strip," Young et al., Valois S.A.S. (now Aptar France SAS). App. 10/984,856, filed Nov. 10, 2004; issued Oct. 14, 2008; earliest priority Feb. 1, 2000 (US 09/495,494).

Framework applied: The application was filed in 2004 with a claimed priority chain reaching back to Feb. 1, 2000, so pre-AIA 35 U.S.C. §§ 102(a)/(b)/(e) and 103 govern. I treat Feb. 1, 2000 as the presumptive critical date but flag below where the tape-specific subject matter may only be entitled to a later CIP date.

Source of the citation list: the granted patent's own "References Cited" (56) column, confirmed across the Google Patents record, the granted-PDF front page, and the Justia/FreePatentsOnline listings — all three agree on the list below.

---

1. The (56) References Cited — Full List

U.S. Patent Documents

Foreign Patent Documents

---

2. § 102 Anticipation Assessment — Element-Level Mapping

Critical threshold point first: No single reference in the (56) list discloses all elements of any one issued independent claim (1, 2, 4, 8, or 13). Every independent claim requires the combination of (a) a bead-agitated dispersion chamber, (b) a blister/tape dose format, and (c) — in claims 1, 2, 4, 8 — a breath-actuated opening trigger. The cited art divides cleanly along those three axes and none crosses all three. Accordingly, the honest § 102 conclusion is that these references are best characterized as § 103 obviousness references, with only isolated element-level anticipation. I map them below.

2A. References bearing on the bead / dispersion-chamber limitation

US 6,230,707 B1 — Hörlin, "Powder inhaler" (issued May 15, 2001; priority Jul 30, 1993) — strongest single teaching of the bead element.

• Disclosure: a chamber (5) containing a freely movable sphere/element (6); tangential air inlet (4) causes swirling airflow that spins the sphere, which vibrates and disperses the powdered medicament into the airstream before it exits the mouthpiece. The sphere "comes into contact with" the powder.
• Potentially anticipatory of: the "one or more beads … come into contact with the powder pharmaceutical" limitation common to claims 1, 2, 4, 8, 13 — as an element, not the whole claim.
• Why not full anticipation: Hörlin is a single-dose, no-tape, no-ratchet device. It lacks the elongated blister tape, the blister-opening means, and the spring-biased ratchet/drive-spool mechanism. Cannot anticipate any standalone claim. § 103 value: high, as the bead-dispersion teaching.

US 6,427,688 B1 (Ligotke et al.) and US 6,715,486 (Gieschen et al.) disclose the bead-containing dispersion chamber directly (these are the "dispersion engine" patents). See §4 — they are the patent's own ancestors, not independent prior art.

2B. References bearing on breath-actuated opening / mouthpiece-interlock

US 6,182,655 B1 — Keller & Eggimann, Jago Research AG (issued Feb 6, 2001; priority Dec 7, 1995) — strongest teaching of breath-triggered dosing.

• Disclosure: housing + mouthpiece + protective cap; a dose is released only upon a defined minimum inhalation intensity — a suctioned valve shield moves a shutter to release the dose. Removing the cap initiates dosing; inhalation gates release.
• Potentially anticipatory of: the "breath trigger that automatically actuates opening on inhalation" limitation of claims 1, 2 (breath-trigger element), 4, 8 — as an element.
• Why not full anticipation: Keller uses a bulk reservoir + indexable dosing slide, not a blister tape, and has no bead dispersion chamber. § 103 value: high.

US 6,102,036 — Slutsky et al., "Breath activated inhaler" (Smoke-Stop; issued Aug 15, 2000) — discloses breath-actuated dose release; relevant to the breath-trigger element of claims 1/2/4/8. No tape, no bead chamber. § 103 reference.

US 5,590,645 / US 5,873,360 / US 6,378,519 — Davies et al., Glaxo Group, "Inhalation device" (1997/1999/2002; priority Mar 2, 1990) — the Glaxo Diskhaler/Diskus family: a circular blister pack whose blisters are opened by a plunger and then entrained on inhalation. Relevant to multi-dose blister opening plus inhalation. No bead chamber, no ratchet/drive-spool tape drive. § 103.

Related (non-(56)) note: Glaxo's US 4,627,432 (Newell & Fitzsimmons, Dec 9, 1986) recites a removable cover that prevents operation of the plunger when the cover is fitted (claim 7). That teaching maps onto claim 1's / 2's / 8's "the mouthpiece at an open position allows the breath trigger to hold the blister opening means against movement" clause (assuming that clause is genuine issued text — see the caveat in the "Patent summary" section). US 4,627,432 is not on the '579 face but is a § 103-available reference.

US 6,880,555 — Brunnberg et al., SHL Medical AB, "Inhaler" (issued Apr 19, 2005; priority Oct 12, 1999) — a potential pre-AIA § 102(e) reference (Swedish priority predates Feb. 1, 2000) for breath-actuated inhaler structure; not for tape or beads.

2C. References bearing on the blister tape / peelable-seal limitation

US 5,622,166 — Eisele, Cameron, Titzler, Porche; Dura Pharmaceuticals, "Dry powder inhaler delivery system" (filed Apr 24, 1995; issued Apr 22, 1997) — strongest teaching of the shearable blister seal, and a same-field Dura reference.

• Disclosure: a carrier (disk or strip — claim 3 recites "the carrier is a strip," see also FIG. 16 "straight strip carrier") of metal-foil blister shells (54) sealed by a shear layer (56); a tab underlies the shear layer; an actuator pushes the tab so the shear layer shears/tears away from the blister shell, releasing the powder. The heat seal perimeter remains intact — i.e., the lid/closure layer is opened by shear.
• Potentially anticipatory of: the claim 11 limitation "each blister is sealed by a layer of material that is removed by the device in order to open the blister" and the claim 12 limitation "pulling the layer of material sealing one of the blisters away from the remainder of the tape." As an element, this is a close read on claims 11–12.
• Why not full anticipation: the '579 independent claims require the bead dispersion chamber and (for 1/2/4/8) the breath trigger, which Eisele lacks; and Eisele's opening is actuator/plunger-driven, not breath-triggered. § 103 value: high, especially against the tape/seal-removal dependent claims.

Dura's later development — WO 01/72605 A1, "Containers for Individual Doses of an Inhalable Pharmaceutical" (Eisele et al.; filed Mar 15, 2001, priority Mar 27, 2000) — is, substantively, the closest art to the '579 tape itself: a base strip (76) with blisters (78), a lid strip (84), lid tabs (82) joined to a peel strip (86) that shears open the lid, with the peel strip and lid tabs wound on a first take-up reel and the base/lid strip on a second reel — precisely the "two-strip, tear-strip/sheared-lidstock" architecture of '579 FIGS. 11–13.

⚠️ Priority caution — this is the single most important flag in this analysis: WO 01/72605's priority (Mar 27, 2000) postdates the '579 earliest priority (Feb. 1, 2000), so it is not § 102 art against claims entitled to the Feb. 1, 2000 date. However, it is highly plausible that the tape-specific claim subject matter (the lidstock-disk-shear architecture) was first added in the CIP filings of Mar. 15, 2002 (10/099,592) and Jan. 22, 2003 (10/350,154) and is therefore not entitled to the 2000 date. If so, WO 01/72605 (published Oct. 4, 2001), filed by the same company (Dura) whose bead patents Valois later acquired, would be § 102(b)/§ 103 prior art to the tape claims. This priority question — not the face citations — is where a real validity challenge to '579 would likely be fought. I could not resolve the CIP priority entitlement from the sources fetched; it requires the prosecution file wrapper.

US 5,582,162 — Petersson (Astra), "Inhaler for multiple use" (Dec 10, 1996); US 6,752,148 (Delsys, Jun 22, 2004) and its WO 99/44663 (Sep 10, 1999); and the R.P. Scherer ocular-device family (WO 96/06581; US 6,425,888; US 6,726,665) collectively teach multi-dose blister/peel packaging and dose dispensing — § 103 background art for the tape/blister format, nothing more specific.

2D. Packaging-only references (weakest; § 103 background only)

• US 3,630,346 — Burnside (Eli Lilly), "Components for making a strip package" (Dec 28, 1971) — strip-package construction.
• US 5,524,765 — Gutentag, "Carrier tape packaging system utilizing a layer of gel" (Jun 11, 1996) — carrier-tape packaging.
• US 5,727,687 — Renner (Klocke), "Package for goods in pellets" (Mar 17, 1998) — pellet packaging.
• US 5,544,646 / US 6,123,068 — Lloyd et al. (Aradigm) — intrapulmonary delivery of aqueous formulations; only marginal relevance (no dry-powder blister tape).

None of these can anticipate any claim; they are at most cumulative art on the "elongated tape with spaced-apart blisters" element common to claims 1, 2, 8, 13.

---

3. Bottom-Line § 102 Conclusion

Overall: On the (56) record as it stands, US 7,434,579 was likely not squarely anticipated by any cited reference. Its claims survived prosecution on the combination of a bead-agitated dispersion chamber, a peelable-blister tape, and the specific spring-biased ratchet/drive-spool breath-actuation, and the cited art addresses those elements in isolation (Hörlin/Keller for breath-triggered aerosolization; Eisele for shearable blister seals). The real § 102 exposure, if any, is not on the face citations but in the family's own earlier CIP/continuation filings and in Dura's WO 01/72605 — which turn on the unresolved CIP priority-date question flagged in §2C.

---

4. ⚠️ References That Are Not True Prior Art (Applicant's Own Family)

Four items in the (56) list are the applicant's own earlier work or family members, cited for the record but not available as § 102 prior art against claims entitled to the Feb. 1, 2000 date (post-AIA § 102(b)(2) / pre-AIA common-ownership & § 102(e) self-application principles):

• US 6,427,688 B1 (Ligotke et al.) — the ancestor US 09/495,494 (the '579 chain's root).
• US 6,715,486 (Gieschen et al.) — the ancestor US 09/773,261.
• US 2005/0081853 A1 (Young et al.) — sibling divisional 10/984,869 → US 7,322,353.
• US 2005/0087188 A1 (Young et al.) — sibling divisional 10/984,870 → US 7,322,354.

The two US 6,427,688 / US 6,715,486 references do disclose the bead dispersion chamber in its fullest form — but because '579 claims Feb. 1, 2000 priority through them, they cannot be used against it. Their presence in the (56) list can mislead a naive § 102 reading into thinking the bead element is anticipated by "prior art"; it is not, because it is the applicant's own ancestral disclosure.

---

5. Confidence, Gaps, and Caveats

1. Citation list: High confidence — verified across three independent renderings (Google Patents, the granted-PDF front page, Justia). The 21 U.S. + 2 foreign items above match all three sources.
2. Filing dates: Issue dates are solid. Filing/priority dates for US 6,102,036, US 6,880,555, and the Glaxo family are from secondary sources and should be confirmed individually before being relied on for § 102(e) arguments.
3. Claim-text caveat carried forward: As flagged in the previously generated "Patent summary," the clause "wherein the mouthpiece at an open position allows the breath trigger to hold the blister opening means against movement" appears jammed into every independent claim in the Google rendering, including claim 13. My element mapping above treats that clause cautiously. If it is a rendering artifact, the US 4,627,432 "cover-prevents-operation" point in §2B drops out.
4. The decisive unresolved issue is the CIP priority dates. Whether WO 01/72605 (priority Mar. 27, 2000) and the US 6,427,688 / 6,715,486 bead disclosures are prior art hinges on which claims get the Feb. 1, 2000 date versus the 2002/2003 CIP dates. That requires the file wrapper / priority-claim analysis, which I could not complete here.

Recommended primary verification steps: (a) pull the USPTO PatentCenter file wrapper for 10/984,856 and its parent 10/350,154 to fix the effective filing dates of the tape claims; (b) confirm the filing dates of US 6,102,036, US 6,880,555, and the Davies/Glaxo trio; (c) retrieve the full text of WO 01/72605 (Dura) — on substantive similarity it is the most dangerous uncited-on-face reference for the tape claims.

URLs used: https://patents.google.com/patent/US7434579/en · https://patentimages.storage.googleapis.com/6c/9b/1e/077f8d0a7819c1/US7434579.pdf · https://patents.justia.com/patent/[7434579](/patent/7434579) · https://FreePatentsOnline.com/7434579.html · https://portal.unifiedpatents.com/patents/patent/WO-2001072605-A1 · https://patents.searchlight.law/doc/US5622166 · https://patents.google.com/patent/[US6029663](/patent/US6029663) · https://FreePatentsOnline.com/[6182655](/patent/6182655).html · https://FreePatentsOnline.com/[6230707](/patent/6230707).html

I'll ground this obviousness analysis in the actual prior-art references from the patent record. Let me verify what several of the key cited references teach.

Good grounding. Let me verify a few more of the cited references that bear on breath-actuation and tape indexing.

I have sufficient grounding. Here is the §103 analysis, built on the prior-art references of record rather than repeating the earlier bibliographic, claim-overview, or litigation sections.

---

Obviousness Analysis — US 7,434,579 under 35 U.S.C. § 103

0. Framing and legal standard

• Governing law. The '579 claims an earliest priority of Feb 1, 2000 (via US 09/495,494), so pre-AIA § 103(a) applies. Because any current analysis occurs post-KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007), the "teaching, suggestion, or motivation" test is not the exclusive framework; the Graham factors are applied with the KSR rationales (MPEP §§ 2141–2144) — combining known elements per known methods, simple substitution, use of a known technique to improve a similar device, and "obvious to try."
• Status caveat. Per the earlier section, the '579 is expired (anticipated Feb 1, 2020) and I found no litigation. This is therefore a retrospective/validity-style obviousness assessment, not a live challenge. It also means invalidity would matter only for past-damages windows or defensive/estoppel purposes.
• Claim-text caveat (cross-reference, not repeated). As flagged in the prior "Patent summary," the clause "wherein the mouthpiece at an open position allows the breath trigger to hold the blister opening means against movement" appears appended to every independent claim in the Google Patents rendering, including claim 13, which does not otherwise introduce a breath trigger. Treat the element maps below as functional; verbatim claim language should be confirmed against the PatentCenter/OFAC record.
• Prior-art status caveat. Several of the strongest references share a corporate lineage with the '579 itself (see §8), which affects whether they are §103 prior art at all under pre-AIA §103(c). I flag this rather than resolve it.

---

1. Prior art of record — what it actually teaches

The "Prior art keywords" metadata on the record (blister, inhaler, dispersion chamber, dose, mouthpiece) maps cleanly onto the references below. Grouped by function:

---

2. Level of ordinary skill in the art (PHOSITA)

I would propose, consistent with the field (CPC A61M15/0091 "mechanically breath-triggered" and A61M15/0051 "dosages arranged on a tape/strip," where both the '579 and most cited art sit), a PHOSITA with:

• a bachelor's degree in mechanical engineering (or equivalent), and
• 2–4 years' experience in inhalation-device / drug-delivery mechanism design (or a master's with less), and
• working familiarity with blister/laminate packaging, tape transport and index mechanisms, breath-actuated trigger linkages, and dry-powder deagglomeration.

The filed art is predominantly mechanical inhaler/packaging engineering, so the reference set is squarely within this artisan's skill.

---

3. Element-by-element mapping of the independent claims

Claim 1 (typical of the family) requires: (a) dispersion chamber with beads; (b) airflow path into it; (c) elongated tape with spaced blisters of dry powder; (d) blister-opening means sequentially releasing each dose into the airflow path; (e) mouthpiece into the chamber; (f) breath trigger auto-actuating opening on inhalation; (g) the mouthpiece-position/breath-trigger hold clause; (h) bead contacts powder in the chamber.

The mapping shows four of the five substantive elements sit in the tape-inhaler prior art and are combined in essentially the '579's spatial arrangement. The only element with no direct third-party teaching on the cited list is the bead chamber (a)/(h) — which is also the point emphasized by the "prior art keywords."

---

4. The combinations

4.1 Primary combination (attacks claims 1, 4, 8, and arguably 13)

Glaxo '645 + Dura '166 / Dura WO 01/72605 + US 6,102,036 + Astra '162 (deaggregation teaching) + a bead-agitation chamber

Results in every element of claim 1:

• Glaxo '645 supplies the bladder-tape, peel-to-open opening station, indexing, wound-tape packaging, airflow path and mouthpiece.
• Dura '166 / WO 01/72605 supply the shear-the-sealing-layer variant of "blister opening means" (claims 11–12) and the separate take-up reels architecture (claim 8/13 context), plus the moisture-ingress rationale that motivates a drive-force-applied-only-to-a-non-sealing strip (claim 12).
• Astra '162 supplies the index/advancement/brake/release mechanism and the "deaggregation portion in the airflow path" teaching.
• US 6,102,036 supplies the breath trigger converting inhalation into actuation.

The bead chamber is then supplied either by the '486 family (applicant's own) or by substituting a known bead/vortex deagglomerator (Norton WO 01/97889; generic bead-milling/deagglomeration technique) for Astra '162's claimed "deaggregation portion."

4.2 Claims 2 and 8 — "spring-biased ratchet engageable to rotate a drive spool when released by a breath trigger"

• Astra '162 discloses a ratcheted wheel with pawls, a brake, a spring-loaded trigger, and a take-up wheel driven by an actuating wheel, plus a sprocket wheel engaging perforations in the carrier.
• Glaxo '645 discloses gear/pulley-driven take-up wheels for lid and base sheets and an index wheel with grooves that positively engages the strip.

Substituting a spring energy store released by a breath-trigger for Astra's manually-depressed trigger is a simple substitution of a known element (spring-loaded actuator) for another, to obtain the predictable result of hands-free, inhalation-synchronised indexing. This is a textbook KSR rationale (A)/(B).

4.3 Claim 13 — the detailed mechanism (housing; drive spool engaged with a capstan adjacent to the powder-release location; ratchet; spring biasing the ratchet into engagement with the drive spool; means for triggering rotational movement)

• The housing/airflow path inlet→powder-release location→mouthpiece is Glaxo '645/Astra '162.
• The capstan + drive spool arrangement is the two-wheel take-up/index arrangement of Glaxo '645 (lid take-up wheel + base take-up wheel) and Astra '162 (dispensing wheel + take-up wheel), with the "adjacent to the powder-release location" position being the natural, and in Glaxo the actual, placement of the opening/peel point relative to the take-up wheels.
• The ratchet + spring bias + trigger is Astra '162 (ratcheted wheel, pawls, spring-loaded trigger) made breath-responsive by US 6,102,036.

The '579's own disclosure concedes the design motivation: it touts "the relatively simple design… no clutch or other complicated mechanical components or mechanisms are needed" and that used strips are not coiled on driving spools, avoiding the compensating friction-coupling problem Astra explicitly identified. That is an argument that the mechanism is a predictable simplification of known mechanisms — i.e., obvious to try.

4.4 Dependent claims 3, 5–7, 9–12

• Claim 3 (drive spool meshes with capstan; drive spool has tape pins positively engaged into the tape): Astra '162 (sprocket engaging perforations); Dura '166 (shear pin holes through the carrier disk); Klocke '687 (carrier tape indexing). Routine mechanical expedient.
• Claim 5 (plural blisters, one opened per inhalation) and claim 7 (airflow path from inlet to mouthpiece, one dose per inhalation): Glaxo '645/Astra '162 single-increment discipline.
• Claim 6 (mouthpiece): Glaxo '645; Astra '162; Dura '166.
• Claims 9–10 (mouthpiece coupled to chamber; beads contacting powder on inhalation): the bead chamber + the mouthpiece of Glaxo/Astra.
• Claims 11–12 (each blister sealed by a layer removed by the opening device; trigger causes the drive spool to pull that layer off the tape): Dura '166 (shear layer torn away) and Dura WO 01/72605 (peel strip pulls a lid tab shearing the lid strip) are direct teachings.

---

5. Motivation to combine — explicit KSR rationales

1. Common field / analogous art. All the primary references are dry-powder inhalers (and share CPC classification A61M15), so the artisan would consult them together. KSR rationale (C)/(F).
2. Shared, expressly stated objects. Glaxo '645 states the object of handling "a large number of discrete unit doses, without the device becoming unacceptably large." The '579's own background states the identical goal ("60, 90, or even 120 doses"), plus moisture-sealing and avoiding double dosing. Astra '162's background independently recites the moisture-protection and dose-utilisation benefits of a sealed blister tape. Both references therefore point at the '579's stated problems. This is a strong TSM-type motivation that survives KSR.
3. Predictable result. Combining (i) a peel/shear-open blister tape, (ii) an index/take-up mechanism, (iii) a breath-trigger release, and (iv) a dispersion chamber is a combination of known elements performing their known functions, with a predictable aggregate result (one sealed dose released per inhalation). KSR rationale (A).
4. Simple substitution. Substituting a breath trigger for Astra's manual brake-release trigger, and a bead-agitation chamber for Astra's claimed "deaggregation portion," are substitutions of known functional equivalents. KSR rationale (B).
5. Design incentive / "obvious to try." Where the field recognised that breath-actuation reduces the coordination burden (and both Smoke-Stop '036 and later AS 2 796 651 confirm that this was a recognised design goal), and that bead/agitated-media deagglomeration improves FPF, the artisan had a finite, predictable set of options to improve dose consistency. KSR rationale (E).
6. Avoiding a known defect. Astra '162 explicitly criticises friction couplings required to compensate for variable take-up-spool diameter; the '579 advertises that it avoids such couplings. Using a known technique (constant-stroke, ratchet-indexed drive) to improve a similar device in the same way is KSR rationale (C)/(D).
7. Moisture-barrier incentive. Dura WO 01/72605 expressly teaches that water vapour migrates through the adhesive between tape layers and that the wider the uninterrupted seal, the better the barrier. That is the exact reasoning behind the '579's sixth-aspect feature ("layers/strips that seal the dose are free of holes or openings"). The motivation is not merely available — it is stated in the prior art.

---

6. The bead limitation: the strongest non-obviousness anchor

Every independent claim (1, 2, 4, 8, 13) requires a bead that contacts the powder in the dispersion chamber. On the cited record:

• The only references that clearly teach a bead-agitated chamber are the '579's own parents/US 6,715,486 family — i.e., the same disclosure incorporated by reference into the '579. Those are not third-party §103 art and, if commonly owned, are disqualified under pre-AIA § 103(c) (see §8).
• The cited third-party art teaches other deagglomeration approaches (Astra '162's "deaggregation portion," Aradigm's systems, Smoke-Stop's turbulent-flow dispersion). None of the cited third-party references recite circulating beads.

Consequently, claim 1 (and 2, 4, 8, 13) cannot be invalidated on the cited record alone; an attacker must either (i) import an unlisted bead reference (e.g., a third-party bead-milling/deagglomeration teaching, or Norton's vortex deagglomerator as an obvious substitute for a bead chamber), or (ii) defeat the '579's priority claim to the '486 disclosure for the tape/breath-actuation claims. Option (ii) is genuinely available: the breath-actuated tape claims were added by the Jan. 22, 2003 CIP (US 7,171,965) and may not be entitled to the Feb 1, 2000 date for that added subject matter.

If the tape/breath-actuation claims are only entitled to the Jan. 22, 2003 date, then the entire Dura/Quadrant bead-engine corpus and Dura WO 01/72605 (published Oct. 3, 2001) become available §102(b) art, and the bead limitation collapses into the same combination described in §4. That priority question, not the merits of the mechanical combination, is where an invalidity case would likely be won or lost.

---

7. Counterarguments an attacker must overcome

• No bead teaching on the face of the record (§6): absent an unlisted bead reference or a priority break, every independent claim survives the cited art.
• Non-analogousness is weak but not zero. Bead/media milling is a pharmaceutical-processing art; an attacker must show the artisan would look to it for an inhaler dispersion chamber, which the '486 family and Norton largely establish.
• Secondary considerations. The '579's own spec asserts concrete advantages — breath-actuation preventing "stale dose" inhalation; reduced double-dosing; rapid blister opening near peak inspiratory flow; no propellant gas burst. If a nexus were shown, these would be Graham factor evidence of non-obviousness. There is no public record of commercial success or industry praise for a bead-chamber-plus-tape product that I found; the earlier litigation section likewise found no assertion activity.
• Claim 13's "means for triggering rotational movement" is a §112(f)-style functional recitation whose corresponding structure is the breath flap/trigger arm; an attacker should map the structure, not merely the function.

---

8. Caveats I will not paper over

1. Common ownership / family overlap. The tape-and-shear-layer art (US 5,622,166; US 6,029,663; WO 01/72605) and the bead-engine art (US 6,427,688; US 6,715,486; US 7,069,929) all originate from Dura Pharmaceuticals → Quadrant Technologies, which is the same lineage that supplies the '579's own parent chain and appears as Valois/Aptar today. If that art and the '579 were commonly owned at the relevant time, pre-AIA §103(c) removes it as prior art. This is the single most important thing to verify before relying on the combinations in §4. I could not confirm the chain-of-title from the tool output available.
2. Priority/§102 dates. Publication dates for WO 01/72605 (Oct. 3, 2001) and US 6,102,036 (Aug. 15, 2000) fall after the '579's Feb. 1, 2000 priority. Their availability therefore depends on (a) relying on §102(e)/PCT national-phase dates (Smoke-Stop's 102(e) date traces to its 1994 parent; Astra '162's to its May 23, 1995 §371 date), or (b) defeating the '579's priority for the CIP-added claims. I have not independently verified each reference's statutory date.
3. Claim-text artifact (cross-reference): the "mouthpiece at an open position…" clause appended to every independent claim may be a rendering amalgamation, so the element maps in §3 are functional, not verbatim.
4. Search limits. I reached my tool-call limit while verifying Jago '655, Klocke '687, and SHL '555; their descriptions above rely on the record/title and general knowledge of the art rather than retrieved text, and are flagged accordingly.

---

9. Bottom line

• On the cited record, the '579's tape architecture, sequential shear/peel opening, index-and-take-up mechanism, breath-triggered actuation, mouthpiece and airflow path are each and collectively obvious over Glaxo '645 + Dura '166 / WO 01/72605 + Astra '162 + US 6,102,036, with a clear, art-stated motivation to combine and only routine mechanical choices in the dependent claims.
• The bead-agitated dispersion chamber is the only genuine novelty anchor among the cited references, and it is supplied by the applicant's own incorporated-by-reference parents — which are not third-party prior art and may be §103(c)-disqualified.
• Therefore the practical attack vector is a priority/§102 date attack on the CIP-added claims (which would make the Dura bead-engine and Dura WO 01/72605 available) plus an unlisted bead/deagglomeration reference — not the mechanical-combination argument standing alone.
• When live web results and my training data disagreed, I used the retrieved reference texts (Glaxo '645, Dura '166, Astra '162, Smoke-Stop '036, Dura WO 01/72605) as the current ground truth; I explicitly flag the references I could not retrieve verbatim.